BioCentury | Feb 6, 2020
Deals

Beyond Keytruda: How Merck envisions innovation and growth after a spinout

As Merck becomes the latest large pharma to split in two, separating its key growth drivers and innovative programs from its slower-growing businesses, the slimmed-down innovative company will rely on the fruits of recent and...
BC Extra | Dec 12, 2018
Company News

Management tracks: Merck creates new commercial roles to follow Schechter's exit

Merck & Co. Inc. (NYSE:MRK) said President of Global Human Health Adam Schechter will step down at the end of the year. The company will restructure his former position into two new roles effective Jan....
BC Week In Review | Feb 16, 2017
Company News

NexImmune deal

An investor group acquired immuno-oncology company NexImmune for an undisclosed amount. The group includes Sol Barer, former Celgene Corp. (NASDAQ:CELG, Summit, N.J.) chairman and CEO and current chairman of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel...
BC Extra | Feb 14, 2017
Financial News

Barer among investors acquiring NexImmune

An investor group including former CEOs of Celgene Corp. (NASDAQ:CELG) and Medtronic plc (NYSE:MDT) has acquired immuno-oncology company NexImmune Inc. (Gaithersburg, Md.) for an undisclosed amount. The group includes Sol Barer, the former Celgene chairman...
BioCentury | Jul 11, 2016
Finance

Advising Israel

BC Staff  A new Israeli VC fund is leveraging a broad base of biopharma advisers to give its portfolio companies an advantage in development, partnering and commercialization activities. Israel Biotech Fund is raising its first...
BC Innovations | Jun 9, 2016
Strategy

Sanofi's post-reconstruction era

Lauren Martz, Senior Writer  Five years after taking the helm as Sanofi 's president of global R&D, Elias Zerhouni is rounding out his strategy to revamp the division and rebuild the pipeline with the appointment...
BioCentury | Jun 8, 2015
Emerging Company Profile

Financing innovation in China

Yabao Pharmaceutical Group Co. Ltd. is seeking VCs to join it in financing a new spinout that has aspirations to participate in global development of novel drugs. Newco Suzhou Yabao Pharmaceutical R&D Co. Ltd. is...
BC Innovations | Feb 5, 2015
Distillery Therapeutics

Therapeutics: Viral protein 1 (VP1)

Infectious disease INDICATION: Enterovirus In vitro studies suggest the antiviral compound pleconaril could help treat enterovirus 68 (EV68) infection. In a cell-based assay, pleconaril inhibited the activity of the Fermon CA62-1 strain of EV68 at...
BioCentury | Feb 2, 2015
Politics, Policy & Law

Dr. Califf goes to Washington

FDA has had three deputy commissioners during the Obama administration ; each was expected to play a major role in shaping the agency, and none of them lived up to expectations. Last week's announcement that...
BC Innovations | Apr 17, 2014
Cover Story

Contaminating cancer genomes

Two European teams have pinpointed the DNA-protective enzyme 7,8-dihydro-8-oxoguanine triphosphatase as a chemically tractable target whose inhibition kills cancer cells by accelerating DNA damage. 1,2 Both groups have identified collections of small molecule inhibitors of...
Items per page:
1 - 10 of 2187
BioCentury | Feb 6, 2020
Deals

Beyond Keytruda: How Merck envisions innovation and growth after a spinout

As Merck becomes the latest large pharma to split in two, separating its key growth drivers and innovative programs from its slower-growing businesses, the slimmed-down innovative company will rely on the fruits of recent and...
BC Extra | Dec 12, 2018
Company News

Management tracks: Merck creates new commercial roles to follow Schechter's exit

Merck & Co. Inc. (NYSE:MRK) said President of Global Human Health Adam Schechter will step down at the end of the year. The company will restructure his former position into two new roles effective Jan....
BC Week In Review | Feb 16, 2017
Company News

NexImmune deal

An investor group acquired immuno-oncology company NexImmune for an undisclosed amount. The group includes Sol Barer, former Celgene Corp. (NASDAQ:CELG, Summit, N.J.) chairman and CEO and current chairman of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel...
BC Extra | Feb 14, 2017
Financial News

Barer among investors acquiring NexImmune

An investor group including former CEOs of Celgene Corp. (NASDAQ:CELG) and Medtronic plc (NYSE:MDT) has acquired immuno-oncology company NexImmune Inc. (Gaithersburg, Md.) for an undisclosed amount. The group includes Sol Barer, the former Celgene chairman...
BioCentury | Jul 11, 2016
Finance

Advising Israel

BC Staff  A new Israeli VC fund is leveraging a broad base of biopharma advisers to give its portfolio companies an advantage in development, partnering and commercialization activities. Israel Biotech Fund is raising its first...
BC Innovations | Jun 9, 2016
Strategy

Sanofi's post-reconstruction era

Lauren Martz, Senior Writer  Five years after taking the helm as Sanofi 's president of global R&D, Elias Zerhouni is rounding out his strategy to revamp the division and rebuild the pipeline with the appointment...
BioCentury | Jun 8, 2015
Emerging Company Profile

Financing innovation in China

Yabao Pharmaceutical Group Co. Ltd. is seeking VCs to join it in financing a new spinout that has aspirations to participate in global development of novel drugs. Newco Suzhou Yabao Pharmaceutical R&D Co. Ltd. is...
BC Innovations | Feb 5, 2015
Distillery Therapeutics

Therapeutics: Viral protein 1 (VP1)

Infectious disease INDICATION: Enterovirus In vitro studies suggest the antiviral compound pleconaril could help treat enterovirus 68 (EV68) infection. In a cell-based assay, pleconaril inhibited the activity of the Fermon CA62-1 strain of EV68 at...
BioCentury | Feb 2, 2015
Politics, Policy & Law

Dr. Califf goes to Washington

FDA has had three deputy commissioners during the Obama administration ; each was expected to play a major role in shaping the agency, and none of them lived up to expectations. Last week's announcement that...
BC Innovations | Apr 17, 2014
Cover Story

Contaminating cancer genomes

Two European teams have pinpointed the DNA-protective enzyme 7,8-dihydro-8-oxoguanine triphosphatase as a chemically tractable target whose inhibition kills cancer cells by accelerating DNA damage. 1,2 Both groups have identified collections of small molecule inhibitors of...
Items per page:
1 - 10 of 2187